Sexually Transmitted Diseases

STI rates have been growing significantly in the United States and around the world. To fix the problem, we need a renewed focus on this therapeutic area, according to top public health officials.

According to results from the Rwanda Population-based HIV Impact Assessment (RPHIA), 76% of all adults living with HIV in Rwanda have achieved viral load suppression.

Investigators used national electronic health record data to determine the proportion of American adults who have been tested for HIV.

Long-term immunogenicity of a 2-dose schedule of the quadrivalent HPV vaccination was demonstrated in a new study in Canada that followed up on an earlier clinical trial.

Jump-starting HIV treatment in hospital emergency department settings could be a key to curbing the spread of the virus.

The approval allows treatment-experienced adults living with HIV who are virally suppressed to switch to doravirine or doravirine/lamivudine/tenofovir disoproxil fumarate.

Along with other heart ailments, new research finds that people living with HIV have a greater risk of atrial fibrillation.

The SLATE study evaluated whether a clinical algorithm can help clinicians determine eligibility for same-day treatment among people living with HIV and initiate ART when appropriate.

People are living long lives with HIV care, but it is important to acknowledge aging-related challenges of HIV prevention, testing, treatment, and care.

The prevalence of sexually transmitted infections is rising, and a new study suggests a higher risk for HIV-positive MSM whose partners use PrEP.

A study conducted in Kenya demonstrated that appealing to women who present at family-planning clinics to obtain birth control can increase the percentage who will use PrEP.

There was no difference in HIV acquisition among women who used progestogen-only injectables, implants, or intrauterine devices.

In the doxycycline as PrEP arm, there was a 73% reduction (p = .02) in syphilis, Neisseria gonorrhoeae, and Chlamydia trachomatis infections.

In 2018, the UK recorded 4484 new cases of HIV, representing a 28% decrease compared with the 6271 new diagnoses documented in 2015.

That daily PrEP dose may not be necessary, according to a new study that examined time-driven and event-driven dosing in a high-risk population.

The in vitro activity of nano-mupirocin, as well as its distribution to vaginal mucus, strongly support its development for the treatment of MDR gonorrhea.

Allowing pharmacists to provide PrEP care is a feasible alternative for improving access to the treatment, according to a recent trial that was well-received by patients and pharmacists.

Advances in treatment mean people are living longer than ever with HIV—but the flip side is an increased risk of certain diseases, especially ones related to aging.

The study has achieved its primary objective, demonstrating that administration every 8 weeks is as effective in maintaining viral suppression compared with monthly administration.

Lactic acid produced by bacteria in the vagina may help protect women from Chlamydia trachomatis infection, a new study suggests.

The vaccine was based on a recombinant protein subunit (CTH522) and evaluated in a prime-boost immunization schedule.

Transitioning from a child born with HIV into an adult living with HIV often means less adherence to antiretroviral medication therapies and a lower level of viral suppression. A new study delves into some possible reasons why.

There has been increasing interest in the association between neural tube defects, dolutegravir, and integrase inhibitors as a class since 4 cases were reported in 2018.

Research on a tenofovir disoproxil fumarate intravaginal ring for PrEP hit a hurdle when 8 of 12 women unexpectedly developed vaginal ulcers.

Blocking the transport of critical metals like zinc into the cell could be a way to prevent growth and therefore infection by Neisseria gonorrhoeae.